Vivos Therapeutics (VVOS) Change in Receivables (2020 - 2026)

Vivos Therapeutics (VVOS) has reported Change in Receivables for 7 consecutive years, with -$331000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Change in Receivables fell 1642.11% year-over-year to -$331000.0 in Q2 2026; TTM through Jun 2026 was -$195000.0, a 164.14% decrease from a year earlier, with the FY2025 full-year figure at $217000.0, down 4.82% from the prior year.
• Change in Receivables was -$331000.0 for Q2 2026 at Vivos Therapeutics, down from $188000.0 in the prior quarter.
• Over five years, Change in Receivables peaked at $501000.0 in Q3 2025 and troughed at -$553000.0 in Q4 2025.
• A 5-year average of -$38833.3 and a median of -$25000.0 in 2023 frame the typical range for Change in Receivables.
• Across the five-year window, Change in Receivables sank 2283.33% in 2024 and jumped 749.15% in 2025, its largest moves.
• Over 5 years, Change in Receivables stood at -$409000.0 in 2022, then soared by 93.64% to -$26000.0 in 2023, then grew by 7.69% to -$24000.0 in 2024, then slumped by 2204.17% to -$553000.0 in 2025, then surged by 40.14% to -$331000.0 in 2026.
• The last three Change in Receivables figures came in at -$331000.0 (Q2 2026), $188000.0 (Q1 2026), and -$553000.0 (Q4 2025), per Business Quant data.